ADHS: diagnostische und therapeutische Herausforderungen in der Praxis

Literatur

• 1 Huss M, Lehmkuhl U. Aufmerksamkeits-Defizit-Hyperaktivitäts-Störung (ADHS) in Deutschland.  Public Health Forum. 2005;  49 0-11
• 2 Lehmkuhl G. Aufmerksamkeitsdefizit. Hyperaktivitätsstörung bei Kindern und Jugendlichen: diagnostische und therapeutische Leitlinien.  . 2007;  149 (Suppl. 2) 10-13
• 3 Remschmidt H, Heiser P. Differenzierte Diagnostik und multimodale Therapie hyperkinetischer Störungen. Dt.  Ärzteblatt. 2004;  37 A2071-2079
• 4 Sobanski E, Alm B. Aufmerksamkeitsdefizit- / Hyperaktivitätsstörung (ADHS) bei Erwachsenen.  Nervenarzt. 2004;  7 697-715
• 5 Wilens T E, Biederman J, Spencer T J. Attention deficit/hyperactivity disorder across the lifespan.  Annu Rev Med. 2002;  53 113-131
• 6 Hurtig T, Ebeling H, Taanila A. et al . ADHD symptoms and subtypes: relationship between childhood and adolescent symptoms.  J Am Acad Child Adolesc Psychiatry. 2007;  46 1605-1613
• 7 Barkley R A, Guevremont D C, Anastopoulos A D. et al . Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey.  Pediatrics. 1993;  92 212-218
• 8 Grützmacher H. Unfallgefährdung bei Aufmerksamkeits- und Hyperaktivitätsstörung. Dt.  Ärzteblatt. 2001;  98 A2195-2197
• 9 Loney J, Ledolter J, Kramer J R, Volpe R J. Retrospective ratings of ADHD symptoms made at young adulthood by clinic-referred boys with ADHD-related problems, their brothers without ADHD, and control participants.  Psychol Assess. 2007;  19 269-280
• 10 Wolraich M L, Wibbelsman C J, Brown T E. et al . Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications.  Pediatrics. 2005;  115 1734-1746
• 11 Brook J S, Duan T, Zhang C. et al . The association between attention deficit hyperactivity disorder in adolescence and smoking in adulthood.  Am J Addict. 2008;  17 54-59
• 12 Robinson T W. ADHD and addiction.  Nature Medicine. 2002;  8 24-25
• 13 Schubiner H, Tzelepis A, Milberger S. et al . Prevalence of ADHD and conduct disorder among substance abusers.  J Clin Psychiatry. 2000;  61 244-251
• 14 Jensen P S, Arnold L E, Swanson J M. et al . 3-Year Follow-up of the NIMH MTA Study.  J Am Acad Child Adolesc Psychiatry. 2003;  46 989-1002
• 15 Molina B SG, Flory K, Hinshaw S P. et al . Delinquent Behavior and Emerging Substance Use in the MTA at 36 Months: Prevalence, Course, and Treatment Effects.  J Am Acad Child Adolesc Psychiatry. 2007;  46 1028-1040
• 16 Arnold L E, Abikoff H B, Cantwell C K. et al . National Institute of Mental Health Collaborative Multimodal Treatment Study of children with ADHD (the MTA). Design challenges and choices.  Arch Gen Psychiatry. 1997;  54 865-870
• 17 Banaschewski T, Coghill D, Santosh P. et al . Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline.  Eur Child Adolesc Psychiatry. 2006;  15 476-495
• 18 Wilens T E, Kwon A, Tanguay S. et al . Characteristics of adults with Attention Deficit Hyperactivity Disorder plus substance abuse disorder: the role of psychiatric comorbidity.  Am J Addict. 2005;  14 319-327
• 19 Holtmann M, Bölte S, Goth K. et al . Prevalence of the Child Behavior Checklist-pediatric bipolar disorder phenotype in a German general population sample.  Bipolar Disord. 2007;  9 895-900
• 20 Scheffer R E. Concurrent ADHD and bipolar disorder.  Curr Psychiatry Rep. 2007;  9 415-419
• 21 Augustin M, Gehrmann J. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörungen (ADHS) und Substanzabusus.  Kinderärztl Praxis. 2008;  79 26-30
• 22 Frölich J, Lehmkuhl H. Epidemiologie und pathogenetische Aspekte von Substanzmissbrauch und – abhängigkeit bei ADHS.  Sucht. 2006;  52 367-375
• 23 Pliszka S. (AACAP Work Group on Quality Issues) . Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.  J Am Acad Child Adolesc Psychiatry. 2007;  46 894-921
• 24 Charach A, Ickowicz A, Schachar R. Stimulant treatment over five years: adherence, effectiveness, and adverse effects.  J Am Acad Child Adolesc Psychiatry. 2004;  43 559-567
• 25 Johnston C, Hommersen P, Seipp C. Acceptability of behavioral and pharmacological treatments for attention-deficit/hyperactivity disorder: relations to child and parent characteristics.  Behav Ther. 2008;  39 22-32
• 26 Remschmidt H, Schmidt M H, Poustka F, Hrsg. Multiaxiales Klassifikationsschema für psychische Störungen des Kindes- und Jugendalters nach ICD-10 der WHO. Bern; Huber 2006
• 27 Thiruchelvam D, Charach A, Schachar R J. Moderators and mediators of long-term adherence to stimulant treatment in children with ADHD.  J Am Acad Child Adolesc Psychiatry. 2001;  240 922-928
• 28 Schweitzer J, von Schlippe A. Lehrbuch der systemischen Therapie und Beratung Bd.2 Das störungsspezifische Wissen. Göttingen; Vandenhoeck & Ruprecht 2007
• 29 Tsirigotis C, von Schlippe A, Schweitzer-Rothers J, Hrsg. Coaching für Eltern Mütter, Väter und ihr „Job”. Heidelberg; Carl-Auer 2006
• 30 Armenteros J L, Lewis J E, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study.  J Am Acad Child Adolesc Psychiatry. 2007;  46 558-565
• 31 Prasad S, Harpin V, Poole L. et al . The Sunbeam Study Group: A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD).  Curr Med Res Opin. 2007;  23 379-394
• 32 Buitelaar J K, Danckaerts M, Gillberg C. et al . A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD.  Eur Child Adolesc Psychiatry. 2004;  13 249-257